2142 — HBM Holdings Share News
0.000.00%
Last trade - 00:00- HK$9.03bn
- HK$6.91bn
- $157.98m
Brief: HBM Holdings Says Weihao Xu Appointed As CFO
Brief: HBM Holdings Decided To Close Study Without Enrolling New Patients Of Its China Tanfanercept Phase III Clinical Trial
Brief: HBM Holdings Announces License Agreement With CSPC Nbp Pharmaceutical
Brief: Hbm Holdings Posts HY Loss For Period $73.1 Million
Brief: Capital Group Companies' Long Position In H-Shares Of HBM Holdings Falls To 4.96% - Filing
Brief: HBM Holdings Says U.S. FDA Granted IND Clearance For B7H4X4-1BB Bispecific Antibody HBM7008
Brief: HBM Says Got IND Approval Of From NMPA To Begin Phase I Clinical Trial Of B7h4x4-1Bb Bispecific Antibody
Brief: HBM Holdings Commenced Collaborations On Antibody-Drug Conjugate Projects
Brief: Harbour BioMed Doses First Patient In Phase I Trial Of B7H4x4-1BB Bispecific Antibody
Brief: HBM Holdings Says Xiaoxiang Chen Has Resigned As Executive Director
Brief: The Capital Group Companies' Long Position In H-Share Of Hbm Holdings Reduces To 5.57% - Filing
Brief: HBM Holdings Says Co And AstraZeneca Entered Global Out-License Agreement
Brief: HBM Holdings Gets IRB Approval For Commencement Of Phase I Trial Of B7h4x4-1Bb Bispecific Antibody In Australia
Brief: HBM Holdings Gets IND Approval For Anti-TSLP Fully Human Monoclonal Antibody In Asthma From China's NMPA
Brief: Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial
Brief: HBM Holdings Says Mai-Jing Liao Resigned As An Executive Director
Brief: HBM Holdings Says Positive Results From Phase I Trial For HBM4003
Brief: HBM Holdings Says China's NMPA Has Approved Group's IND Application For HBM4003
Brief: HBM Holdings Says Harbour Biomed Receives Chinese Regulatory Approval To Begin Phase II Clinical Trial Of Hbm9161